Apolipoprotein M can discriminate HNF1A‐MODY from Type 1 diabetes

Abstract

Missed diagnosis of maturity-onset diabetes of the young (MODY) has led to an interest in biomarkers that enable efficient prioritization of patients for definitive molecular testing. ApolipoproteinM (apoM) was suggested as a biomarker for hepatocyte nuclear factor1 alpha (HNF1A)-MODY because of its reduced expression in Hnf1a(-/-) mice. However, subsequent human studies examining apoM as a biomarker have yielded conflicting results. We aimed to evaluate apoM as a biomarker for HNF1A-MODY using a highly specific and sensitive ELISA. ApoM concentration was measured in subjects with HNF1A-MODY (n=69), Type1 diabetes (n=50), Type2 diabetes (n=120) and healthy control subjects (n=100). The discriminative accuracy of apoM and of the apoM/HDL ratio for diabetes aetiology was evaluated. Mean (standard deviation) serum apoM concentration (μmol/l) was significantly lower for subjects with HNF1A-MODY [0.86 (0.29)], than for those with Type1 diabetes [1.37 (0.26), P=3.1×10(-18) ) and control subjects [1.34 (0.22), P=7.2×10(-19) ). There was no significant difference in apoM concentration between subjects with HNF1A-MODY and Type2 diabetes [0.89 (0.28), P=0.13]. The C-statistic measure of discriminative accuracy for apoM was 0.91 for HNF1A-MODY vs. Type1 diabetes, indicating high discriminative accuracy. The apoM/HDL ratio was significantly lower in HNF1A-MODY than other study groups. However, this ratio did not perform well in discriminating HNF1A-MODY from either Type1 diabetes (C-statistic=0.79) or Type2 diabetes (C-statistic=0.68). We confirm an earlier report that serum apoM levels are lower in HNF1A-MODY than in controls. Serum apoM provides good discrimination between HNF1A-MODY and Type1 diabetes and warrants further investigation for clinical utility in diabetes diagnostics.